Moneycontrol

Moneycontrol PRO

you are here: HomeNewsBusinessCompaniesBiocon, Mylan in deal for 3 bio-generic insulin drugs

SHOW NAMES

Trending Topics

business

Biocon, Mylan in deal for 3 bio-generic insulin drugs

Biocon, a global biopharmaceutical enterprise today entered into a licencing agreement with Mylan for three bio-generic insulin products. Kiran Mazumdar, CMD, Biocon, in an interview to CNBC-TV18, says that the company will receive licencing fees from Mylan, however, they will not receive any milestone payments.

first published: Feb 14, 2013 10:31 am

LATEST VIDEOS

A collection of the most-viewed Moneycontrol videos.

Watch and Follow our leading shows

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347